• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Assessing the Impact of Decision Aid Use on Post Prostatectomy Patient Reported Outcomes.评估决策辅助工具使用对前列腺癌术后患者报告结局的影响。
Urology. 2022 Jul;165:187-192. doi: 10.1016/j.urology.2022.02.008. Epub 2022 Feb 24.
2
Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance.使用 EPIC-50 尿困扰量表需谨慎:排尿功能障碍如何改变其性能。
J Urol. 2017 Dec;198(6):1397-1403. doi: 10.1016/j.juro.2017.07.041. Epub 2017 Jul 18.
3
The Relationship and Psychosocial Impact of Arousal Incontinence After Radical Prostatectomy.根治性前列腺切除术后的觉醒性尿失禁的关系和心理社会影响。
J Sex Med. 2020 Jan;17(1):94-98. doi: 10.1016/j.jsxm.2019.09.001. Epub 2019 Nov 15.
4
Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO.在一项前瞻性、非随机试验LAPPRO中,对根治性前列腺切除术后有症状男性的副作用及不适的准备情况。
Acta Oncol. 2016 Dec;55(12):1467-1476. doi: 10.1080/0284186X.2016.1213415. Epub 2016 Aug 16.
5
Comparison of urinary and sexual patient-reported outcomes between open radical prostatectomy and robot-assisted radical prostatectomy: a propensity score matched, population-based study in Victoria.开放根治性前列腺切除术与机器人辅助根治性前列腺切除术患者尿控和性功能结局的比较:维多利亚州基于人群的倾向评分匹配研究。
BMC Urol. 2022 Feb 7;22(1):18. doi: 10.1186/s12894-022-00966-0.
6
Quality of life following radical prostatectomy.根治性前列腺切除术后的生活质量。
Crit Rev Oncol Hematol. 2002 Aug;43(2):141-51. doi: 10.1016/s1040-8428(02)00026-4.
7
Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial.机器人辅助与开放性根治性前列腺切除术治疗后尿失禁和勃起功能障碍:一项前瞻性、对照、非随机试验。
Eur Urol. 2015 Aug;68(2):216-25. doi: 10.1016/j.eururo.2015.02.029. Epub 2015 Mar 12.
8
Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study.临床局限性前列腺癌根治性前列腺切除术后的泌尿和性功能:前列腺癌结局研究
JAMA. 2000 Jan 19;283(3):354-60. doi: 10.1001/jama.283.3.354.
9
Development and Validation of Crosswalks for Patient-reported Sexual and Urinary Outcomes Between Commonly Used Instruments.跨常用仪器评估患者报告的性和尿失禁结局的换算表的制定和验证。
Eur Urol. 2019 May;75(5):723-730. doi: 10.1016/j.eururo.2018.12.002. Epub 2018 Dec 17.
10
Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial.在瑞典 LAPPRO 试验中,24 个月随访时开放与机器人辅助根治性前列腺切除术的功能与肿瘤学结果。
Eur Urol Oncol. 2018 Oct;1(5):353-360. doi: 10.1016/j.euo.2018.04.012. Epub 2018 Jun 11.

引用本文的文献

1
Knowledge map of self-reported outcomes in patients with prostate cancer: a bibliometric analysis (2014-2023).前列腺癌患者自我报告结局的知识图谱:一项文献计量分析(2014 - 2023年)
Front Urol. 2025 Aug 15;5:1574626. doi: 10.3389/fruro.2025.1574626. eCollection 2025.

本文引用的文献

1
Factors Associated with Decision Aid Use in Localized Prostate Cancer.局限性前列腺癌中与决策辅助工具使用相关的因素
Urol Pract. 2022 Jan;9(1):108-115. doi: 10.1097/upj.0000000000000283. Epub 2022 Jan 1.
2
Patient- and Surgeon-Level Variation in Patient-Reported Sexual Function Outcomes Following Radical Prostatectomy Over 2 Years: Results From a Statewide Surgical Improvement Collaborative.患者报告的根治性前列腺切除术后 2 年的性功能结局的患者和外科医生水平的变化:来自全州手术改善合作的结果。
JAMA Surg. 2022 Feb 1;157(2):136-144. doi: 10.1001/jamasurg.2021.6215.
3
Implementation of prostate cancer treatment decision aid in Michigan: a qualitative study.密歇根州前列腺癌治疗决策辅助工具的实施:一项定性研究。
Implement Sci Commun. 2021 Mar 6;2(1):27. doi: 10.1186/s43058-021-00125-w.
4
Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy From a Statewide Improvement Collaborative.从全州改善协作中评估前列腺根治性切除术后 3 个月患者报告的尿结局的患者和外科医生特异性变化。
JAMA Surg. 2021 Mar 1;156(3):e206359. doi: 10.1001/jamasurg.2020.6359. Epub 2021 Mar 10.
5
Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms.寻求下尿路症状治疗的个体中症状严重程度与困扰的关系。
Neurourol Urodyn. 2020 Nov;39(8):2161-2170. doi: 10.1002/nau.24466. Epub 2020 Aug 6.
6
Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.扩展前列腺癌指数综合量表-26(EPIC-26)在线版:一种基于互联网的工具用于评估局限性前列腺癌治疗后健康相关生活质量的验证
Urology. 2019 May;127:53-60. doi: 10.1016/j.urology.2019.02.004. Epub 2019 Feb 18.
7
Longitudinal regret and information satisfaction after deciding on treatment for localized prostate cancer with or without a decision aid. Results at one-year follow-up in the PCPCC trial.在局部前列腺癌治疗中使用或不使用决策辅助工具后的纵向后悔和信息满意度。PCPCC 试验一年随访结果。
Patient Educ Couns. 2019 Mar;102(3):424-428. doi: 10.1016/j.pec.2018.10.006. Epub 2018 Oct 4.
8
Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy.癌症治疗副作用患者报告的单一项目测量的有效性和有用性。
Cancer. 2018 Mar 1;124(5):991-997. doi: 10.1002/cncr.31133. Epub 2017 Nov 13.
9
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.基于个人患者档案——前列腺癌的决策支持:一项多中心随机试验。
J Urol. 2018 Jan;199(1):89-97. doi: 10.1016/j.juro.2017.07.076. Epub 2017 Jul 25.
10
Decision aids for people facing health treatment or screening decisions.为面临医疗治疗或筛查决策的人们提供的决策辅助工具。
Cochrane Database Syst Rev. 2017 Apr 12;4(4):CD001431. doi: 10.1002/14651858.CD001431.pub5.

评估决策辅助工具使用对前列腺癌术后患者报告结局的影响。

Assessing the Impact of Decision Aid Use on Post Prostatectomy Patient Reported Outcomes.

机构信息

Department of Urology, University of Michigan, Ann Arbor, MI; VA Ann Arbor Medical Center, Ann Arbor, MI.

Department of Urology, University of Michigan, Ann Arbor, MI; VA Ann Arbor Medical Center, Ann Arbor, MI.

出版信息

Urology. 2022 Jul;165:187-192. doi: 10.1016/j.urology.2022.02.008. Epub 2022 Feb 24.

DOI:10.1016/j.urology.2022.02.008
PMID:35219768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9296586/
Abstract

OBJECTIVE

To evaluate whether completing a decision aid, Personal Patient Profile - Prostate (P3P), prior to prostatectomy, affects self-reported bother from post-prostatectomy urinary incontinence and erectile dysfunction.

MATERIALS AND METHODS

This retrospective analysis included data from men with newly diagnosed clinically localized, very low to intermediate risk prostate cancer who elected for prostatectomy within the Michigan Urological Surgery Improvement Collaborative between 2018-2021. Multivariable logistic regression models were used to estimate the association between P3P use and bother from post prostatectomy erectile dysfunction and urinary incontinence as measured by the Expanded Prostate Cancer Index Composite (EPIC-26).

RESULTS

Among the 3987 patients included, 7% used P3P (n = 266). Men who used P3P reported significantly less bother from erectile dysfunction at 6 months vs non-users (aOR 0.42 [95% CI 0.27-0.66]). At 12 months, the effect of P3P on bother from erectile dysfunction was not statistically significant (aOR 0.62 [95% CI 0.37-1.03]). Men who used P3P did not have a statistically significant difference in bother from urinary incontinence (3-month: aOR 0.56 [95% CI 0.30-1.06]; 6-month; aOR 0.79 [95% CI 0.31-1.97]).

CONCLUSION

Within the stated limitations of this study, we find that use of a decision aid for localized prostate cancer was associated with decreased odds of men being bothered from sexual dysfunction but not urinary incontinence at 6 months post prostatectomy.

摘要

目的

评估在前列腺切除术之前完成决策辅助工具,即个人患者前列腺状况简介(P3P),是否会影响前列腺切除术后尿失禁和勃起功能障碍的自我报告困扰程度。

材料和方法

本回顾性分析纳入了 2018 年至 2021 年期间在密歇根州泌尿外科学术改进合作组织中选择前列腺切除术的新发临床局限性、极低至中度风险前列腺癌男性患者的数据。多变量逻辑回归模型用于估计 P3P 使用与前列腺切除术后勃起功能障碍和尿失禁困扰之间的关联,以扩展前列腺癌指数综合量表(EPIC-26)进行测量。

结果

在纳入的 3987 例患者中,有 7%(n=266)使用了 P3P。与非使用者相比,使用 P3P 的男性在 6 个月时报告的勃起功能障碍困扰程度显著降低(优势比 0.42 [95%置信区间 0.27-0.66])。在 12 个月时,P3P 对勃起功能障碍困扰程度的影响没有统计学意义(优势比 0.62 [95%置信区间 0.37-1.03])。使用 P3P 的男性在尿失禁困扰程度方面没有统计学上的显著差异(3 个月:优势比 0.56 [95%置信区间 0.30-1.06];6 个月:优势比 0.79 [95%置信区间 0.31-1.97])。

结论

在本研究的既定限制范围内,我们发现使用局部前列腺癌决策辅助工具与前列腺切除术后 6 个月男性性功能障碍困扰的可能性降低相关,但与尿失禁无关。